Long-term prevention of diabetic nephropathy: An audit

K. J. Schjoedt, H. P. Hansen, L. Tarnow, P. Rossing, H. H. Parving

    Publikation: Bidrag til tidsskriftArtikelForskningpeer review


    Aims/hypothesis: In type 1 diabetic patients with microalbuminuria not receiving antihypertensive treatment, an increase in urinary AER (UAER) of 6-14%/year and a risk of developing diabetic nephropathy (DN) of 3-30%/year have been reported. We audited the long-term effect of blocking the renin-angiotensin-aldosterone system (RAAS) with an ACE inhibitor (ACEI) or angiotensin II receptor blocker (ARB) in microalbuminuric type 1 diabetic patients on progression of microalbuminuria and development of DN. Methods: All patients with type 1 diabetes and persistent microalbuminuria (30-300 mg/24 h) were identified (n=227) in 1995 at Steno Diabetes Center and followed for 11 years. Development of DN was defined as a UAER of >300 mg/24 h in two of three consecutive urine samples. Results: Age and duration of diabetes at baseline (mean±SD) were 46±15 and 28±13 years, respectively. During follow-up 14 patients emigrated and 58 (26%) died. Over the same period 79% were treated with an ACEI or ARB. There was a mean decline in UAER of 4%/year. Sixty-five patients (29%) progressed to overt DN, corresponding to 3.1%/year. However, 29 of them regressed to normo- or microalbuminuria on intensified antihypertensive treatment. Glycaemic control and blood pressure remained nearly unchanged. Conclusions/interpretation: In our outpatient clinic, the implementation of RAAS-blocking treatment in type 1 diabetic patients with microalbuminuria successfully reduced long-term progression to overt DN to a rate similar to those previously reported in randomised, double-blind intervention trials of shorter duration using RAAS blockade.

    Sider (fra-til)956-961
    Antal sider6
    Udgave nummer6
    StatusUdgivet - 1 jun. 2008

    Fingeraftryk Udforsk hvilke forskningsemner 'Long-term prevention of diabetic nephropathy: An audit' indeholder.